tbuckley/cabot-search huggingface dataset:
FRI0391 GLYCA, A Novel Marker of Inflammation, Is Elevated in Systemic Lupus Erythematosus
Authors: C.P. Chung, M.J. Ormseth, M.A. Connelly, A. Oeser, J.F. Solus, J. Otvos, P. Raggi, C.M. Stein
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> GlycA is a novel marker of systemic inflammation detected by nuclear magnetic resonance spectroscopy (NMR). It arises from the N-acetyl methyl signals from glycosylated acute phase proteins. Several glycoproteins, including α-1 antichymotrypsin, haptoglobin, α-1-antitrypsin, transferrin, and α1-acid glycoprotein (AGP, orosomucoid) contribute significantly to increase the GlycA signal during inflammation. In the general population, GlycA is correlated with inflammatory markers such as C-reactive protein (CRP) and associated with coronary heart disease and diabetes. The utility of GlycA in patients with systemic lupus erythematosus (SLE) has not been defined. <h3>Objectives</h3> To test the hypothesis that GlycA concentrations were elevated in patients with SLE and associated with other markers of inflammation and with coronary atherosclerosis. <h3>Methods</h3> We compared concentrations of GlycA in 116 patients with SLE and 84 control subjects frequency-matched for age, sex, and race. GlycA was detected by NMR. SLE disease activity index (SLEDAI) and the SLE Collaborating Clinics damage index (SLICC) were calculated. Acute phase reactants [erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP)], a panel of cytokines and a lipid panel were measured. Electron beam computer tomography (EBCT) was used to quantify coronary artery calcification, a measure of coronary artery atherosclerosis. <h3>Results</h3> Patients with SLE had higher concentrations of GlycA [398 (350-445)] than control subjects [339 (299-391)] μmol/L, p&lt;0.001. In patients with SLE, concentrations of GlycA were significantly associated with ESR (rho=0.43), CRP (rho=0.59), interleukin-6 (rho=0.27), e-selectin (rho=0.28), intracellular adhesion molecule-1 (rho=0.30), HDL cholesterol (rho=-0.26), triglycerides (rho=0.45), systolic (rho=0.23), and diastolic blood pressure (rho=0.21), all p&lt;0.05, but not with creatinine, SLEDAI, SLICC, or coronary calcium scores. <h3>Conclusions</h3> Concentrations of GlycA are higher in patients with SLE than control subjects and associated with markers of inflammation but not with SLE disease activity or chronicity scores or coronary artery calcification. <h3>Disclosure of Interest</h3> C. Chung: None declared, M. Ormseth: None declared, M. Connelly Employee of: LabCorp, A. Oeser: None declared, J. Solus: None declared, J. Otvos Employee of: LabCorp, P. Raggi: None declared, C. M. Stein: None declared
High Frequency of Resistance of Human Squamous Carcinoma Cells to the Anti-proliferative Action of Transforming Growth Factor β
Authors: M Reiss, E B Stash
Journal: Cancer Communications (1990)

Transforming Growth Factor beta is a potent autocrine inhibitor of the growth of untransformed keratinocytes. We found each of eight human squamous carcinoma cell lines to be refractory to the anti-proliferative action of Transforming Growth Factor beta. Although each of these carcinoma cell lines expressed the 53-65 kDa (type I) and the 280-300 (type III) Transforming Growth Factor beta-receptor proteins, the 73-85 kDa (type II) species was detectable in only one of these cell lines. Furthermore, although Transforming Growth Factor beta-sensitive non-neoplastic mouse keratinocytes expressed type II binding proteins, human keratinocytes did not. Our findings suggest that resistance to the growth-inhibitory actions of Transforming Growth Factor beta is a common feature of human squamous carcinoma cell lines but does not correlate with the expression of cell-surface receptors for this growth factor.
Several Cytogenetic Subclones May Be Identified Within Plasma Cells From Patients With Monoclonal Gammopathy of Undetermined Significance, Both at Diagnosis and During the Indolent Course of This Condition
Authors: Marc Zandecki, Jean-Luc Laı̈, Franck Geneviève, Franck Bernardi, Hélène Volle-Rémy, Odile Blanchet, Michel François, Alain Cosson, Francis Bauters, Thierry Facon
Journal: Blood (1997)
Activated EGFR as a prognostic marker in human colon cancer
Authors: R. L. Rego, T. C. Smyrk, N. R. Foster, D. J. Sargent, S. N. Thibodeau, S. R. Alberts, H. E. Windschitl, F. A. Sinicrope
Journal: Journal of Clinical Oncology (2008)

22119 Background: The Epidermal Growth Factor Receptor (EGFR, ErbB-1) is a cellular transmembrane receptor that regulates cell growth and survival, and is a therapeutic target. We determined whether EGFR activation, as indicated by EGFR phosphorylation (p-EGFR), is a more clinically important prognostic marker than is EGFR expression. Methods: Archival TNM stage II and III primary colon carcinomas (n=303) from patients treated in 5-fluorouracil-based adjuvant therapy trials conducted by the Mayo Clinic/North Central Cancer Treatment Group were studied. Immunohistochemical analysis of p-EGFR (Tyr-1173) and EGFR (Dako phramDx kit) were performed using tissue microarrays. Staining for Ki-67 and caspase-3 proteins was also performed. Protein expression was correlated with clinicopathological variables and patient survival rates. Results: Membranous EGFR was detected in 214 (70.6%) colon cancers and of these, p-EGFR expression was found in 44 of 139 (31.7%) tumors examined. Increased p-EGFR and EGFR intensity were associated with higher proliferation as indicted by a higher median number of Ki-67-positive tumor cells (p= 0.0058 and p< 0.001, respectively). p-EGFR correlated with proximal tumor site (p=0.0331), but not with other clinicopathological variables. Increased EGFR intensity was correlated with apoptosis, analyzed by caspase-3 (p=0.02), and with poor tumor differentiation (p=0.02). In a univariate analysis, tumor stage and number of involved lymph nodes were significantly associated with disease-free and overall survival (OS). Histologic grade was also associated with OS. Neither p-EGFR nor EGFR expression was prognostic by univariate or multivariate analysis. Conclusions: Activated EGFR (p-EGFR) was detected in nearly one-third of primary colon cancers and was associated with increased tumor cell proliferation. However, neither p- EGFR nor EGFR confered prognostic information. No significant financial relationships to disclose.
OC-074 Enhanced recovery for oesophagogastric surgery (eros)
Authors: T Underwood, F Noble, R Hole, D Sharland, J Kelly, J Byrne
Journal: Gut (2015)

<h3>Introduction</h3> Enhanced recovery is an accepted mechanism to improve perioperative outcomes in surgery. The generalisablity of outcomes after enhanced recovery for oesophagogastric surgery (EROS) has been limited because the majority of series come from a single surgeon or have excluded patients based on surgeon preference. There have been few reports comparing open with minimally invasive surgery in this setting. We review our experience of EROS for all-comers and compare minimally invasive two-stage oesophagectomy (MIO-2) with open Ivor Lewis oesophagectomy (IVL). <h3>Method</h3> The EROS perioperative programme at University Hospital Southampton commenced with a multidisciplinary team meeting followed by multiple rounds of protocol revision, including patient feedback, to include all aspects of the perioperative pathway. All patients undergoing oesophageal or gastric resections were entered into EROS from 20/9/13. Short-term clinicopathologic outcomes were recorded using validated systems. <h3>Results</h3> 78 patients in EROS have undergone the following operations: subtotal gastrectomy (5 patients), total gastrectomy (14), Mckeown oesophagectomy (1), colonic interposition (1), MIO-2 (29), IVL (23), hybrid MIO-2 (5). Overall median length of hospital stay was 9 days (range 4–47) with no deaths. Considering oesophagectomy, patient demographics (age, sex, preoperative body mass index, tumour characteristics, neoadjuvant regime and pathological tumour stage) were comparable between MIO-2 and IVL. ASA grade was higher in patients who underwent MIO-2 (P &lt; 0.05). Adherence to the EROS protocol was equivalent between groups (MIO-2 vs. IVL): EROS commenced in pre-assessment (95.7% vs. 93.1%), Hillrom chair-bed use (90.9% vs. 92.9%), EROS carried out in HDU (90.9% vs. 85.7%). Outcomes for MIO-2 and IVL were comparable for median length of stay (8 [range 6–47] vs. 9 [7–16] days), anastomotic leak (1/28 vs. 0/23), and complications graded by the Clavien-Dindo classification (Grade 1: 13% vs. 3.6%; Grade 2: 56.5% vs. 50%; Grade 3: 3.6% vs. 0%; Grade 4: 7.1% vs. 0% with no complications in 30.4% vs. 35.7% of patients respectively). One patient remains on EROS day 6 post MIO-2. Oncological parameters were comparable between MIO-2 and IVL: resection margin clearance (R0) (71.4% vs 86.4%) and median lymph node yield (28 (range 12–62) vs. 25 (8–64)) respectively. <h3>Conclusion</h3> The introduction of EROS for all patients undergoing oesophageal surgery has led to significant patient benefits, including reduced hospital stay (12 days to 9 days) and fewer postoperative major complications (19.8% to 5.9%) compared to our previously published series. Within EROS open oesophageal resection has comparable outcomes to minimally invasive surgery. <h3>Disclosure of interest</h3> T. Underwood Grant/ Research Support from: MRC, F. Noble Grant/ Research Support from: Cancer Research UK, R. Hole: None Declared, D. Sharland: None Declared, J. Kelly: None Declared, J. Byrne: None Declared.
Assessing the Effects of Psychotherapy
Authors: R Sandell
Journal: Psychotherapy and Psychosomatics (1987)

The principles and background of 'Change after Psychotherapy' (CHAP) are described, and the instruction and procedure are detailed. The ratings are made on the basis of therapy sessions or posttherapy interviews and are guided by variable definitions in the form of numerous examples of manifest signs of various kinds of therapeutic change. The rating variables are: symptom amelioration, increased adaptive capacity, self-insight, resolution of the basic conflict, and the presence of change-facilitating extrathera-peutic conditions.
Effect of Coincident Hypercalcemia and Potassium Depletion on Rat Kidney
Authors: J A RICHARDSON, W D HUFFINES, L G WELT
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THU0542 Is there Any Difference Between Autoimmune or Hemato-Oncology Etiology to Guide us in the Diagnosis of Secondary Macrophage Activation Syndrome?: Table 1
Authors: C.A. Egües Dubuc, V. Aldasoro Cáceres, M. Uriarte Ecenarro, C.F. Meneses Villalba, N. Errazquin Aguirre, I. Hernando Rubio, O. Maiz Alonso, J. Cancio Fanlo, E. Uriarte Isacelaya, M. Yagüe Asensio, J. Belzunegui Otano
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Secondary macrophage activation syndrome (MAS) is a group of diseases, especially due to autoimmune (AI) and hemato-oncology (HO). It would be interesting to find any clinical and analytics data to differentiate both etiologies. <h3>Objectives</h3> To describe and compare demographics, clinical and laboratories features and mortality of patients diagnosed with secondary MAS due to HO and AI diseases at the Donostia University Hospital. <h3>Methods</h3> A cohort of patients diagnosed with MAS was studied by reviewing medical reports in the period Dec/2008-Jan/2015. We analyzed and compared only patients with AI and HO diseases. The variable studied were diagnosis, age, sex, fever, organomegaly, hospital and overall mortality, analytical findings, hospital stay, days from admission to diagnosis and days from diagnosis to the end of the study or death after discharge. Quantitative variables are shown with the median and interquartile range. For the bivariate analysis Wilcoxon and Chi square test were used. Median survival in months and Hazar Ratio (HR) was calculated with the Kaplan Meier plot. <h3>Results</h3> Nineteen patients were found diagnosed with MAS, 6 and 9 were due to AI and HO diseases respectively. The AI diseases found were: 3 Systemic Lupus Erythematosus, 2 Adult Still9s Disease and 1 disease associated with IgG4. HO diseases found were: 3 acute myeloid leukemias, 2 B cells Not Hogkin Lymphoma (NHL), 1 T anb B cells NHL, 1 Natural Killers cells extranodal lymphoma, 1 myelodysplastic syndrome and 1 gastric plasmacytoma. The table shows the descriptive analysis of 19 patients and the bivariate analysis between AI and HO. The median survival of HO diseases was 1.2 months and AI diseases can not be calculated. The mortality of HO and AI diseases was 77.8% and 16.7% respectively with a p=0.04 in the log rank test. The HR of mortality among HO against AI diseases was 6.84. <h3>Conclusions</h3> In the present study the following differences were found: 1) Patients with MAS due to AI diseases have a higher elevated liver enzymes compared to HO disease. 2) Patients with MAS due to HO diseases have a greater pancytopenia compared to AI diseases, especially in leukocytes and neutrophils. 3) Patients with MAS due to HO have a higher mortality compared to AI diseases. <h3>Disclosure of Interest</h3> None declared
Arsenic Trioxide (ATO) Or ATRA For Consolidation Treatment Of Standard Risk Non Elderly Newly Diagnosed APL– Second Interim Analysis Of a Randomized Trial (APL 2006) By The French Belgian Swiss APL Group
Authors: Lionel Ades, Sylvie Chevret, Emmanuel Raffoux, Arnaud Pigneux, Xavier Thomas, Dominique Bordessoule, Norbert Vey, Agnès Guerci-Bresler, Thierry Lamy, Christian Recher, Jean-Francois Lambert, Olivier Tournilhac, Cécile Pautas, Martin Carre, Dominique Bron, Jacques Delaunay, Eric Deconinck, Bruno Quesnel, Stéphane de Botton, Aspasia Stamatoullas, Norbert Ifrah, Christine Chomienne, Herve Dombret, Laurent Degos, Pierre Fenaux
Journal: Blood (2013)
Cancer Mortality Among Native White, Foreign-Born White, and Nonwhite Male Residents of Ohio: Cancer of the Lung, Larynx, Bladder, and Central Nervous System&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: Thomas F. Mancuso, M.D., M.P.H., Elizabeth Jackson Coulter, Ph.D.
Journal: JNCI Journal of the National Cancer Institute (1958)

Cancer Mortality Among Native White, Foreign-Born White, and Nonwhite Male Residents of Ohio: Cancer of the Lung, Larynx, Bladder, and Central Nervous System Thomas F. Mancuso, M.D., M.P.H., Thomas F. Mancuso, M.D., M.P.H. Chief Division of Industrial Hygiene Search for other works by this author on: Oxford Academic PubMed Google Scholar Elizabeth Jackson Coulter, Ph.D. Elizabeth Jackson Coulter, Ph.D. Chief Statistician Division of Vital Statistics, Ohio Department of Health, Columbus, Ohio Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 20, Issue 1, January 1958, Pages 79–105, https://doi.org/10.1093/jnci/20.1.79 Published: 01 January 1958 Article history Received: 03 July 1957 Published: 01 January 1958
SP0003 What is New: Clinical Aspects of RA – Diagnosis, Assessment
Authors: R.F. van Vollenhoven
Journal: Annals of the Rheumatic Diseases (2015)

The diagnosis of RA remains a clinical diagnosis based on the judgement by an experienced clinician. Nevertheless, the recently revised classification criteria for RA are widely used for diagnostic purposes. Several studies have investigated their performance “in real life” and have mostly confirmed that they have good metric properties and that they appear to support one of the explicit goals in their derivation, namely to allow for an earlier diagnosis in the patient with new-onset articular symptoms. The increasing use of musculoskeletal ultrasound in rheumatological practice is beginning to make its impact felt on the diagnostic process as well. In a recent study based on the Bayesian principle of pre-test versus post-test probabilities we showed that the diagnostic certainty in early arthritis was significantly enhanced through the use of ultrasound (Rezaei et al, 2014). The use of fluorescent optical imaging (FOI, “rheumascan”) is still in its infancy but may have usefulness for diagnosing arthritis in the hands (Kisten et al, EULAR2014). These novel imaging modalities, along with conventional and office-based MRI are also impacting on the assessment of RA during the course of the disease. As treatment options have increased, so has the importance of accurate assessment of the patient9s disease state and response to treatment. The EULAR/ACR “Boolean” remission criteria have been studied and found to perform reasonably well, but it appears from several studies that the bar for the patient global assessment may have been set too stringently. Identifying clinically undetectable synovitis (silent synovitis) through imaging may also have implications for therapeutic decisions. Biomarkers are being explored as a complement to the clinical assessment. In recent studies, we demonstrated that a multi-biomarker disease activity score accurately identified patients at risk for radiographic progression (Hambardzumyan, 2014), and more recent data suggest that it may help in choosing the optimal therapy in patients who fail methotrexate. In summary, while the diagnosis and assessment of RA remain first and foremost clinical challenges, innovative imaging technologies and biomarkers are increasingly going to help the clinician make optimal decisions. <h3>Disclosure of Interest</h3> R. van Vollenhoven Grant/research support from: AbbVie, BMS, GSK, Pfizer, Roche, UCB, Consultant for: AbbVie, Biotest, BMS, Crescendo, GSK, Janssen, Lilly, Merck, Pfizer, Roche, UCB, Vertex
Mesoporous Bamboo Charcoal Nanoparticles as a New Near‐Infrared Responsive Drug Carrier for Imaging‐Guided Chemotherapy/Photothermal Synergistic Therapy of Tumor
Authors: Xinghua Dong, Wenyan Yin, Jie Yu, Ruixia Dou, Tao Bao, Xiao Zhang, Liang Yan, Yuan Yong, Chunjian Su, Qing Wang, Zhanjun Gu, Yuliang Zhao
Journal: Advanced Healthcare Materials (2016)

Near‐infrared‐(NIR)‐light‐triggered photothermal nanocarriers have attracted much attention for the construction of more smart and effective therapeutic platforms in nanomedicine. Here, a multifunctional drug carrier based on a low cost, natural, and biocompatible material, bamboo charcoal nanoparticles (BCNPs), which are prepared by the pyrolysis of bamboo followed by physical grinding and ultrasonication is reported. The as‐prepared BCNPs with porous structure possess not only large surface areas for drug loading but also an efficient photothermal effect, making them become both a suitable drug carrier and photothermal agent for cancer therapy. After loading doxorubicin (DOX) into the BCNPs, the resulting DOX–BCNPs enhance drug potency and more importantly can overcome the drug resistance of DOX in a MCF‐7 cancer cell model by significantly increasing cellular uptake while remarkably decreasing drug efflux. The in vivo synergistic effect of combining chemotherapy and photothermal therapy in this drug delivery system is also demonstrated. In addition, the BCNPs enhance optoacoustic imaging contrast due to their high NIR absorbance. Collectively, it is demonstrated that the BCNP drug delivery system constitutes a promising and effective nanocarrier for simultaneous bioimaging and chemo‐photothermal synergistic therapy of cancer.
On Scientific Attitudes
Authors: Ira R. Telford
Journal: JNCI Journal of the National Cancer Institute (1965)

Journal Article On Scientific Attitudes Get access Ira R. Telford, Ph.D. Ira R. Telford, Ph.D. Professor and Chairman Department of Anatomy, The George Washington University School of Medicine, Washington, D.C Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 35, Issue 1, July 1965, Pages 1–5, https://doi.org/10.1093/jnci/35.1.1 Published: 01 July 1965 Article history Received: 11 December 1964 Published: 01 July 1965
ATPS-37THERAPEUTIC VULNERABILITIES AND RESISTANCE MECHANISMS FOR THE PRECISION MEDICINE OF GLIOBLASTOMA
Authors: Anna Lasorella, Antonio Iavarone
Journal: Neuro-Oncology (2015)

Gene fusions generated by chromosomal translocations are the best examples of success for targeted cancer therapy. Our work in malignant glioma identified the first examples of highly oncogenic and recurrent gene fusions that result in constitutive activation of receptor tyrosine kinase genes (FGFR, EGFR and NTRK). Among them, FGFR-TACC is the addicting gene fusion with highest therapeutic value. It is also the gene fusion most frequently represented across other cancer types. Thus, elucidating how FGFR-TACC drives oncogenesis and mechanisms of resistance to FGFR inhibitors are crucial questions with fundamental general implications. By using a combination of unbiased mass spectrometry and functional validation experiments, we have recently identified the tyrosine phosphorylation targets of FGFR-TACC fusions in glioblastoma. We have also generated an inducible and reversible mouse model for FGFR-TACC-mediated tumorigenesis. These mice revealed a strong tumor initiation capacity by FGFR-TACC fusions in the nervous system. They also exposed strict dependency of tumor cells to continuous expression of the FGFR-TACC fusion gene. The mouse model has also allowed us to establish the significance of the new signaling pathways and determine the mechanisms of recurrence of FGFR-TACC-initiated tumors following fusion ablation. The integrated availability of FGFR-TACC substrates and the reversible mouse model of FGFR-TACC-driven tumors are elucidating the mechanisms of resistance triggered by chronic targeting of the fusion gene. The model applied to FGFR-TACC is now being extended to EGFR and NTRK gene fusions to determine similarities and differences and assign accurate therapeutic value to individual chromosomal translocations. Together with the screening and personalized validation paradigm recently completed for the identification, characterization and targeting of FGFR-TACC fusions in patients malignant glioma, the new information will allow us to accurately predict strength of evidence of oncogenic activity and size of anticipated targeting effect for the selection of any “druggable” genetic alteration in GBM patients.
HIV infection among young adults with psychotic disorders
Authors: E Susser, P Colson, L Jandorf, A Berkman, J Lavelle, S Fennig, C Waniek, E Bromet
Journal: American Journal of Psychiatry (1997)

The authors examined HIV infection among young adults with newly diagnosed psychotic disorders.The study was based on a research cohort of 320 first-admission patients aged 20-39 years in a semirural-suburban county. Research assessments and medical records were systematically reviewed for information about HIV status.Despite the fact that few patients were tested for HIV, 12 (3.8%) of the 320 patients had a known HIV infection. In all 12 cases, the HIV infection was contracted before the onset of psychosis. AIDS was the leading cause of mortality in the 320 patients.The HIV epidemic may be having an important effect on the etiology and the course of psychotic disorders.